We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisors Overwhelmingly Reject New Indication for Janssen’s Xarelto
FDA Advisors Overwhelmingly Reject New Indication for Janssen’s Xarelto
Janssen’s third try to expand the indication for its anticoagulant Xarelto floundered Thursday when FDA advisors voted to recommend against its approval, citing concerns about the drug’s risks and missing clinical data.